IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immunocore Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.84+0.44 (+1.50%)
Close on Oct 19, 2026
- Market cap
- $1.52B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
52M of 51M shares
Institutional holders
136
27 new, 31 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 10 sales
Net sold $5.63M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wellington Management Group LLP | 6,430,078 | 13.00% | 13G (passive) amendment | Mar 31, 2025 |
| Wellington Management Company LLP | 5,959,773 | 11.40% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Group Holdings LLP | 5,132,898 | 10.20% | 13G (passive) amendment | Jul 31, 2025 |
| RTW Investments, LP | 4,869,798 | 9.70% | 13G (passive) amendment | Sep 30, 2024 |
| Jallal Bahija | 4,493,139 | 8.20% | 13G (passive) | Dec 31, 2024 |
| Abigail P. Johnson | 4,307,246 | 8.80% | 13G (passive) amendment | Jun 30, 2026 |
| Primecap Management Co/Ca/ | 3,772,234 | 7.51% | 13G (passive) amendment | Jun 30, 2025 |
| Bellevue Asset Management AG | 2,796,803 | 5.60% | 13G (passive) | Aug 20, 2025 |
| Vestal Point Capital, LP | 2,766,868 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Tang Capital Management, LLC | 2,605,608 | 5.20% | 13G (passive) | Oct 17, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMCR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wellington Management Group Llp | 5,721,945 | 11.11% | $181.67M | +1,015,777 | 0.03% |
| Rtw Investments, LP | 4,869,798 | 9.46% | $154.62M | – | 1.32% |
| FMR LLC | 4,307,246 | 8.36% | $136.76M | −521,908 | 0.01% |
| Primecap Management Co/Ca/ | 3,638,241 | 7.06% | $115.51M | −55,000 | 0.07% |
| Bellevue Group AG | 2,788,245 | 5.41% | $88.53M | −8,558 | 1.86% |
| Tang Capital Management LLC | 2,649,368 | 5.14% | $84.12M | – | 3.82% |
| Vestal Point Capital, LP | 1,800,000 | 3.50% | $57.15M | −966,868 | 1.34% |
| Two Sigma Investments, LP | 1,648,983 | 3.20% | $52.36M | +627,718 | 0.04% |
| Millennium Management LLC | 1,597,037 | 3.10% | $50.71M | +359,634 | 0.02% |
| Armistice Capital, LLC | 1,428,000 | 2.77% | $45.34M | +240,000 | 0.55% |
| Caligan Partners LP | 1,381,317 | 2.68% | $43.86M | New | 2.06% |
| Kynam Capital Management, LP | 1,375,000 | 2.67% | $43.66M | +490,063 | 2.41% |
| Bvf Inc/Il | 1,294,463 | 2.51% | $41.10M | – | 1.05% |
| Acadian Asset Management LLC | 1,209,894 | 2.35% | $38.39K | +708,803 | 0.05% |
| Trails Edge Capital Partners, LP | 1,063,234 | 2.06% | $33.76M | +380,637 | 5.36% |
| BlackRock, Inc. | 1,004,598 | 1.95% | $31.90M | +348,289 | 0.00% |
| Point72 Asset Management, L.P. | 990,280 | 1.92% | $31.44M | −111,991 | 0.03% |
| Price T Rowe Associates Inc /Md/ | 831,068 | 1.61% | $26.39K | −88,264 | 0.00% |
| Jupiter Topco LLC | 709,022 | 1.38% | $22.50M | New | 0.01% |
| Cantor Fitzgerald, L. P. | 680,200 | 1.32% | $21.60M | +429,989 | 0.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 136 | 52M | 100.0% | 27 / 52 | 39 / 31 | 11M | 10M |
| Q1 2026 | 142 | 52M | 100.0% | 23 / 51 | 44 / 28 | 9M | 9M |
| Q4 2025 | 149 | 52M | 100.0% | 31 / 48 | 39 / 10 | 5M | 2M |
| Q3 2025 | 132 | 49M | 95.5% | 18 / 41 | 48 / 18 | 4M | 3M |
| Q2 2025 | 133 | 48M | 92.8% | 31 / 45 | 41 / 13 | 6M | 6M |
| Q1 2025 | 116 | 47M | 91.9% | 15 / 43 | 33 / 14 | 4M | 2M |
| Q4 2024 | 115 | 45M | 88.2% | 13 / 37 | 44 / 27 | 5M | 4M |
| Q3 2024 | 130 | 45M | 88.0% | 19 / 47 | 39 / 27 | 8M | 5M |
| Q2 2024 | 139 | 43M | 84.0% | 25 / 58 | 35 / 35 | 12M | 11M |
| Q1 2024 | 149 | 43M | 83.2% | 29 / 64 | 39 / 13 | 9M | 4M |
| Q4 2023 | 133 | 39M | 75.0% | 23 / 52 | 42 / 15 | 5M | 4M |
| Q3 2023 | 125 | 37M | 71.7% | 14 / 50 | 38 / 8 | 4M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMCR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 4,246,274 | 8.25% | $143.57M | 0.38% | Jul 31, 2026 |
| Vanguard Capital Opportunity Fund | 2,335,650 | 4.54% | $74.16M | 0.23% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,121,692 | 2.18% | $32.41M | 0.03% | May 31, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 1,111,200 | 2.16% | $37.57M | 0.51% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 645,268 | 1.25% | $20.49M | 0.17% | Jun 30, 2026 |
| Select Health Care Portfolio | 500,000 | 0.97% | $14.45M | 0.25% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 330,328 | 0.64% | $9.54M | 0.03% | May 31, 2026 |
| MFS New Discovery Fund | 304,295 | 0.59% | $8.79M | 0.41% | May 31, 2026 |
| iShares Biotechnology ETF | 299,288 | 0.58% | $9.50M | 0.10% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 287,200 | 0.56% | $8.30M | 0.16% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 261,570 | 0.51% | $7.56M | 0.03% | May 31, 2026 |
| Fidelity Advisor Health Care Fund | 260,000 | 0.50% | $8.79M | 0.28% | Jul 31, 2026 |
| SmallCap Fund | 217,900 | 0.42% | $7.37M | 0.35% | Jul 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 188,691 | 0.37% | $5.45M | 0.09% | May 29, 2026 |
| Old Westbury Small & Mid Cap Strategies Fund | 159,882 | 0.31% | $5.41M | 0.06% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bahija Jallal | CHIEF EXECUTIVE OFFICER, Director | 12,343 | 0.02% | Feb 19, 2026 |
| Travis Alan Coy | Chief Financial Officer | – | – | Feb 19, 2026 |
| Leger Tina Amber St | CHIEF HR OFFICER | 1,119 | 0.00% | Feb 19, 2026 |
| David M. Berman | HEAD OF R&D | 5,859 | 0.01% | Feb 19, 2026 |
| John Goll | SVP, FINANCE & CAO | 653 | 0.00% | Feb 19, 2026 |
| Siddharth Kaul | Director | – | – | May 28, 2026 |
| Kristine Peterson | Director | – | – | May 28, 2026 |
| William Pao | Director | – | – | May 28, 2026 |
| Roy Steven Herbst | Director | – | – | May 28, 2026 |
| Peter John Ratcliffe | Director | 333 | 0.00% | May 28, 2026 |
| John Irving Bell | Director | 13,452 | 0.03% | May 28, 2026 |
| Julian Baker | Director | – | – | May 19, 2025 |
| Bros. Advisors Lp Baker | Director | – | – | May 19, 2025 |
| Bros. Advisors (GP) LLC Baker | Director | 1,405,421 | 2.73% | May 19, 2025 |
| Brothers Life Sciences LP Baker | Director | – | – | May 19, 2025 |
| 667, L.P. | Director | 2,051,711 | 3.98% | May 19, 2025 |
| Felix Baker | Director | – | – | May 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Goll SVP, FINANCE & CAO | Feb 18, 2026 | Sale | −698 | $32.35 | $22.58K | 653 |
| David M. Berman HEAD OF R&D | Feb 18, 2026 | Sale | −5,965 | $32.35 | $192.97K | 5,859 |
| Bahija Jallal CHIEF EXECUTIVE OFFICER, Director | Feb 18, 2026 | Sale | −11,474 | $32.35 | $371.18K | 12,343 |
| Leger Tina Amber St CHIEF HR OFFICER | Feb 18, 2026 | Sale | −1,000 | $32.35 | $32.35K | 1,119 |
| John Goll SVP, FINANCE & CAO | Feb 17, 2026 | Option exercise | +1,351 | – | – | 1,351 |
| David M. Berman HEAD OF R&D | Feb 17, 2026 | Option exercise | +11,824 | – | – | 11,824 |
| Bahija Jallal CHIEF EXECUTIVE OFFICER, Director | Feb 17, 2026 | Option exercise | +23,817 | – | – | 23,817 |
| Leger Tina Amber St CHIEF HR OFFICER | Feb 17, 2026 | Option exercise | +2,119 | – | – | 2,119 |
| David M. Berman HEAD OF R&D | Dec 5, 2025 | Option exercise | +572 | $17.46 | $9.99K | 572 |
| David M. Berman HEAD OF R&D | Dec 5, 2025 | Sale(10b5-1 plan) | −572 | $40.14 | $22.96K | 0 |
| David M. Berman HEAD OF R&D | Dec 4, 2025 | Sale(10b5-1 plan) | −31,341 | $40.26 | $1.26M | 0 |
| David M. Berman HEAD OF R&D | Dec 4, 2025 | Option exercise | +31,341 | $17.46 | $547.21K | 31,341 |
| David M. Berman HEAD OF R&D | Nov 28, 2025 | Option exercise | +5,521 | $17.46 | $96.40K | 5,521 |
| David M. Berman HEAD OF R&D | Nov 28, 2025 | Sale(10b5-1 plan) | −5,521 | $40.09 | $221.34K | 0 |
| David M. Berman HEAD OF R&D | Nov 26, 2025 | Option exercise | +69,404 | $17.46 | $1.21M | 69,404 |
| David M. Berman HEAD OF R&D | Nov 26, 2025 | Sale(10b5-1 plan) | −69,404 | $40.12 | $2.78M | 0 |
| David M. Berman HEAD OF R&D | Nov 25, 2025 | Sale(10b5-1 plan) | −18,020 | $40.03 | $721.34K | 0 |
| David M. Berman HEAD OF R&D | Nov 25, 2025 | Option exercise | +18,020 | $17.46 | $314.63K | 18,020 |
| David M. Berman HEAD OF R&D | Nov 24, 2025 | Sale(10b5-1 plan) | −100 | $40.00 | $4.00K | 0 |
| David M. Berman HEAD OF R&D | Nov 24, 2025 | Option exercise | +100 | $17.46 | $1.75K | 100 |
| David M. Berman HEAD OF R&D | Sep 30, 2025 | Sale(10b5-1 plan) | −61,849 | $35.23 | $2.18M | 0 |
| David M. Berman HEAD OF R&D | Sep 30, 2025 | Option exercise | +61,849 | $17.46 | $1.08M | 61,849 |
| David M. Berman HEAD OF R&D | Sep 15, 2025 | Option exercise | +200 | $17.46 | $3.49K | 200 |
| David M. Berman HEAD OF R&D | Sep 15, 2025 | Sale(10b5-1 plan) | −200 | $35.01 | $7.00K | 0 |
| David M. Berman HEAD OF R&D | Sep 12, 2025 | Option exercise | +22,532 | $17.46 | $393.41K | 22,532 |
| David M. Berman HEAD OF R&D | Sep 12, 2025 | Sale(10b5-1 plan) | −21,232 | $35.63 | $756.50K | 1,300 |
| David M. Berman HEAD OF R&D | Sep 12, 2025 | Sale(10b5-1 plan) | −1,300 | $36.31 | $47.20K | 0 |
| David M. Berman HEAD OF R&D | Sep 11, 2025 | Sale(10b5-1 plan) | −19,081 | $36.28 | $692.26K | 0 |
| David M. Berman HEAD OF R&D | Sep 11, 2025 | Option exercise | +19,081 | $17.46 | $333.15K | 19,081 |
| David M. Berman HEAD OF R&D | Sep 10, 2025 | Option exercise | +31,338 | $17.46 | $547.16K | 31,338 |
| David M. Berman HEAD OF R&D | Sep 10, 2025 | Sale(10b5-1 plan) | −30,138 | $36.12 | $1.09M | 1,200 |
| David M. Berman HEAD OF R&D | Sep 10, 2025 | Sale(10b5-1 plan) | −1,200 | $36.77 | $44.12K | 0 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +646,290 | $29.74 | $19.22M | 2,051,711 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +8,589 | $29.56 | $253.89K | 178,596 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +92,349 | $29.56 | $2.73M | 2,144,060 |
| 667, L.P. Director | Mar 17, 2025 | Buy | +60,110 | $29.74 | $1.79M | 170,007 |
| Leger Tina Amber St CHIEF HR OFFICER | Apr 1, 2024 | Sale(10b5-1 plan) | −4,375 | $64.06 | $280.26K | 0 |
| Leger Tina Amber St CHIEF HR OFFICER | Apr 1, 2024 | Option exercise | +4,375 | $29.87 | $130.68K | 4,375 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −7,472 | $68.84 | $514.37K | 12,137 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −10,937 | $69.73 | $762.64K | 1,200 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −1,200 | $70.45 | $84.54K | 0 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Option exercise | +36,509 | $17.46 | $637.45K | 36,509 |
| David M. Berman HEAD OF R&D | Feb 28, 2024 | Sale(10b5-1 plan) | −16,900 | $67.61 | $1.14M | 19,609 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −4,448 | $69.45 | $308.91K | 50,490 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −3,394 | $71.97 | $244.27K | 0 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −25,944 | $71.32 | $1.85M | 3,394 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Sale(10b5-1 plan) | −21,152 | $70.42 | $1.49M | 29,338 |
| David M. Berman HEAD OF R&D | Feb 27, 2024 | Option exercise | +54,938 | $17.46 | $959.22K | 54,938 |
| David M. Berman HEAD OF R&D | Feb 26, 2024 | Option exercise | +28,553 | $17.46 | $498.54K | 28,553 |
| David M. Berman HEAD OF R&D | Feb 26, 2024 | Sale(10b5-1 plan) | −26,516 | $70.60 | $1.87M | 2,037 |
| David M. Berman HEAD OF R&D | Feb 26, 2024 | Sale(10b5-1 plan) | −2,037 | $71.31 | $145.26K | 0 |
| Leger Tina Amber St Chief HR Officer | Jan 3, 2024 | Option exercise | +4,375 | $29.87 | $130.68K | 4,375 |
| Leger Tina Amber St Chief HR Officer | Jan 3, 2024 | Sale(10b5-1 plan) | −4,068 | $69.85 | $284.15K | 307 |
| Leger Tina Amber St Chief HR Officer | Jan 3, 2024 | Sale(10b5-1 plan) | −307 | $70.46 | $21.63K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Berman David Affiliate | May 22, 2026 | 69,271 | $2.04M | May 22, 2026 | Same Day Cashless Exercise and Sale |
| Berman David Affiliate | May 21, 2026 | 65,000 | $1.89M | May 21, 2026 | Same Day Cashless Exercise and Sale |
| Berman David Affiliate | Apr 8, 2026 | 25,000 | $796.25K | Apr 8, 2026 | Same Day Cashless Exercise and Sale |
| Berman David affiliate | Mar 11, 2026 | 11,832 | $385.33K | Mar 11, 2026 | Same Day Cashless Exercise and Sale |
| Berman David affiliate | Feb 18, 2026 | 5,965 | $192.95K | Feb 18, 2026 | RSU Vest |
| St Leger Tina affiliate | Feb 18, 2026 | 1,000 | $32.35K | Feb 18, 2026 | RSU Vest |
| Jallal Bahija affiliate | Feb 18, 2026 | 11,474 | $371.15K | Feb 18, 2026 | RSU Vest |
| M. Berman David Officer | Nov 24, 2025 | 136,790 | $5.38M | Nov 24, 2025 | Stock Option Exercise |
| M. Berman David Officer | Sep 10, 2025 | 135,000 | $4.94M | Sep 10, 2025 | Stock Option Exercise |
| Di Donato Brian affiliate | Mar 17, 2025 | 100,000 | $3.00M | Mar 17, 2025 | Same Day Cashless Option Exercise and Sale |
| Di Donato Brian affiliate | Mar 14, 2025 | 56,250 | $1.64M | Mar 14, 2025 | Same Day Cashless Option Exercise and Sale |
| St Leger Tina affiliate | Apr 1, 2024 | 4,375 | $280.28K | Apr 1, 2024 | Same Day Cashless Exercise and Sale |
| Berman David affiliate | Feb 26, 2024 | 120,000 | $8.48M | Feb 26, 2024 | Same Day Cashless Exercise and Sale |
| St Leger Tina affiliate | Jan 3, 2024 | 4,375 | $262.50K | Jan 3, 2024 | Same Day Cashless Exercise and Sale |
| Jallal Bahija affiliate | Dec 27, 2023 | 25,000 | $1.75M | Dec 27, 2023 | Same Day Cashless Exercise and Sale |